The Use of Beneficial Bacteria (Bacillus, Lactic Acid, Escherichia coli) in the Production of Biological Drugs and Vaccines for Chronic Diseases in the Future

In recent years, the utilization of beneficial bacteria in the development of biologics and vaccines for chronic diseases has emerged as a promising and innovative approach. Chronic conditions such as diabetes, cardiovascular diseases, autoimmune disorders, and persistent infections impose a significant burden on healthcare systems worldwide, often leaving traditional pharmaceutical strategies inadequate. By entering the realm of biologics and vaccines, new opportunities arise for targeted interventions and improved management of chronic diseases. Beneficial bacteria such as Bacillus, Lactic Acid Bacteria, and Escherichia coli, with their unique ability to interact with the host’s immune system, serve as promising candidates for enhancing the efficacy of these products. This article explores the potential and applications of these beneficial bacteria in biotechnology. We delve into the characteristics and advantages of Bacillus for its biotechnological capabilities, particularly in enzyme and antibiotic production, highlighting its role in vaccine and therapeutic peptide development against chronic diseases. The article further examines Lactic Acid Bacteria, known for improving digestive and immune health, as potent vectors for vaccine delivery, thereby enhancing immune responses to respiratory and gastrointestinal pathogens. Additionally, the role of Escherichia coli as a biotechnological workhorse is discussed, emphasizing its rapid growth and genetic malleability, which makes it ideal for producing complex biologics for managing chronic disorders. The process of biologic drug production using these bacteria is outlined, emphasizing the need for precise conditions to maintain protein stability and effectiveness. We address the challenges associated with the production and scaling of bacterial-based biologics, including regulatory and safety concerns, economic considerations, and accessibility. The article offers insights into how technological advancements and international collaborations might overcome these obstacles. Finally, we highlight future directions and potential breakthroughs in research, discussing how the integration of beneficial bacteria into biologics and vaccines not only promises enhanced therapeutic and preventive measures for chronic diseases but also paves the way for a transformative impact on global public health strategies.

کلیدواژه ها:

Beneficial bacteria ، Biologics ، Vaccines ، Chronic diseases ، Biotechnology